Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE Suffers Worst Fall Of 2014 As Fear Grips Market

Wed, 15th Oct 2014 16:33

LONDON (Alliance News) - UK stock indices closed significantly lower Wednesday, with the FTSE 100 suffering its worst one-day fall of the year so far. The sell-off was mirrored across Europe as markets were gripped by concern about a slowdown in growth amid disappointing economic data from around the world.

Volatility has returned to the markets in a big way, with the VIX volatility index reaching its highest level since since mid-2012, while global bond yields plunged to their lowest levels of the year and gold reached its highest level in more than a month as investors fled to the traditional safe havens.

The FTSE 100 ended the day down 2.8% at 6,211.64, shedding 181 points, which leaves the UK's leading index at its lowest level in 15 months. The mid-cap FTSE 250 ended the day down 1.7% at 14,426.74, and the small-cap AIM All-Share closed down 2.4% at 681.22, its lowest level in almost two years.

Major European equity markets also suffered heavy falls, with the French CAC 40 down a massive 3.6%, and the German DAX 30 down 2.9%. US stocks continued lower, with the DJIA, S&P 500 and Nasdaq Composite all down about 1.5% at the time of the European close. The DJIA slipped below 16,000 for the first time since February.

European indices started lower Wednesday amid ongoing concerns over the health of the eurozone economy, after early data from Germany showed consumer prices stagnated in September, for the second consecutive month. Those concerns were only compounded by continued declines in the price of oil, with Brent crude hitting a near four-year low in early trade, bottoming at USD83.35 per barrel.

Investors also remain concerned over the spread of Ebola, after a second healthcare worker in the US was confirmed to have caught the virus. The infected person was on an internal US flight on Monday night, and authorities are looking to contact the other passengers on the flight.

Global indices unwound further in afternoon trade after some disappointing US economic data showed retail sales there fell by 0.3% month-on-month in September, exceeding expectations for a 0.1% fall. The New York manufacturing index also contracted sharply in September, coming in at 6.17, down from 27.54 in August, while US producer price growth also turned negative, recording a month fall of 0.1%. The apparent slowing in US economic activity comes as a particular concern to investors given that it coincides with the end of the Federal Reserves quantitative easing programme later this month.

In London, Shire led the FTSE 100 lower from the outset Wednesday, plunging by a quarter at the open after US authorities appeared to get their way when AbbVie Inc said it is reconsidering its takeover of the Irish drug maker. The deal, which valued Shire at GBP32 billion, had been thrown into some doubt after US Treasury Secretary Jack Lew announced new measures last month to make so-called tax inversion deals less appealing. The news that AbbVie actually has gotten cold feed still took the markets by surprise, and Shire ended the day heavily lower at GBP39.43, not far from its mid-June price, when it originally rejected an advance from AbbVie.

Oil stocks were weighed down by oil prices, with Tullow Oil dropping 4.7%, Royal Dutch Shell falling 2.3%, Enquest down 5.7%, and Cairn Energy down 3.3%. BG Group held up relatively well against the sector decline, ending down just 0.5% after announcing that it poached Helge Lund from Norwegian rival Statoil to be its new chief executive from next March. Deutsche Bank sees the appointment as a positive step for BG, calling Lund an "industry heavyweight". Separately, BG Group said it had started production on the Iracema area in block BM-S-11 in the Santos Basin offshore Brazil early.

Royal Mail was the only FTSE 100 stock to record any significant gains, significantly outperforming the market and closing up 1.9% following the news Tuesday that it has sold one of its sites that is "recognised a surplus" for GBP111 million. Analysts at Berenberg say that the sale price was 85% above its own valuation, therefore indicating that Royal Mail shares may be significantly undervalued.

FTSE 250 listed CSR surged 30% after the semiconductor producer said it agreed to be acquired by US-based semiconductor company Qualcomm Inc for GBP1.6 billion in cash, a deal that comes after it has been in talks about a potential takeover with Microchip Technology Inc since August. The 900 pence a share bid from the US semiconductor group comes after CSR rebuffed an approach from Microchip Technology for being too low in August.

Balfour Beatty rose 11% on the news that it has poached the chief executive of defence products company QinetiQ Group to be its own CEO from January 1, 2015, a job that will involve turning the struggling company around after a string of profit warnings, a failed merger attempt from rival Carillion, and the disputed sale of its US project management business. Analysts have been positive over the appointment of new CEO Leo Quinn. Jefferies says he has a good track record as a turnaround specialist. QinetiQ was the worst performer in the FTSE 250, closing down 12%.

The most positive economic news of the day came from the UK Wednesday, where the unemployment rate fell to a six year low of 6.0% in August from 6.2% in July, exceeding expectations for a fall to 6.1%. Average earnings also improved a little faster that expected, rising by 0.9% in August, up from 0.8% in July and beating the expectation for the growth rate to remain unchanged.

A combination of the better UK data and weakness in the US dollar after the poor data across the pond sent the currency pair briefly back above USD1.60, although at the time of the equity market close the pound has weakened again to trade at USD1.5955.

Safe haven demand sent gold up to its highest level in more than a month, peaking at USD1,249.61 per ounce. The firmer price provided support for precious metal miner Fresnillo, which closed up 0.4% after raising its 2014 gold production target to 590,000 ounces.

There may be more volatility still to come Wednesday, with European Central Bank President Mario Draghi due to speak at 1900 BST from an International Monetary Fund event in Washington. The Federal Reserve's Beige Book of economic conditions is also due to be released at the same time.

Looking towards Thursday, eurozone consumer inflation data will be the morning focus, while from the US in the afternoon there is a raft of data including jobless claims and industrial production, as well as a number of speeches from Fed officials.

In the UK corporate calendar Thursday, drinks giant Diageo is due to make an interim management statement, as are Evraz, Mondi, and Man Group, among others. British Sky Broadcasting is due to release first-quarter results.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.